The company plans to issue more than 77 million shares and the expected charter capital after issuance is more than 1,540 billion VND. IMP shares are among the few that have increased strongly against the trend in the context of red covering the stock market on September 4.
 |
The State Securities Commission (SSC) announced that it has received the report on the issuance of shares to increase equity capital from owners' equity (bonus shares) according to the issuance report dated August 13, 2024 of Imexpharm Pharmaceutical Joint Stock Company (code IMP - HoSE). The SSC requested the Company to disclose information and issue shares according to regulations.
According to Imexpharm Pharmaceutical's previous report, the Company's Board of Directors has approved the implementation of the plan to issue bonus shares at a rate of 100%, equivalent to the right exercise ratio of 1:1 (1 old share receives 1 right and 1 right receives 1 new share). The Company plans to issue more than 77 million shares and the expected charter capital after issuance is more than 1,540 billion VND.
Previously, in mid-July, the Company had fixed the right to pay a dividend of 20% for 2023. Accordingly, the 20% rate includes 10% in cash, corresponding to each shareholder owning 1 share will receive 1,000 VND and 10% in shares, corresponding to each shareholder owning 10 shares will receive 1 newly issued share. The cash dividend payment date is July 23, 2024.
In the second quarter of 2024, the Company reported VND517.1 billion in net revenue, up 18% year-on-year. However, the increase in cost of goods sold was stronger, so the gross profit margin decreased by 44% to 40%. Gross profit was recorded at VND200.6 billion, while in the same period it was VND193 billion. Selling expenses and administrative expenses increased by 18% and 22% respectively, so the Company reported a profit after tax of nearly VND66 billion, down 17% year-on-year.
Explaining this fluctuation, the Company said that the profit decreased due to fluctuations in input material prices, reduced production output at IMP 1 factory due to slow growth in the OTC market and the official operation of IMP 4 factory (from the third quarter of 2023), leading to increased depreciation and operating costs.
In the first 6 months of the year, the Company recorded a 10% increase in net revenue to VND1,008 billion. Profit after tax decreased by 19% to VND128 billion and completed 30% of the yearly plan. As of June 30, total assets reached VND2,505 billion, up 5% compared to the beginning of the year. Of which, there was VND258.5 billion in cash and deposits, up 30%.
 |
| IMP shares have increased sharply since the beginning of the year. |
On the stock market, IMP shares are trading at VND93,500/share, up 85% compared to the end of last year. In the session on September 4, IMP was among the few stocks that increased significantly with a 6.83% increase in price amid widespread red on all three stock exchanges.
Source: https://baodautu.vn/duoc-pham-imexpharm-sap-phat-hanh-co-phieu-thuong-ty-le-11-d224005.html
Comment (0)